ConvaTec (CTEC1N) Stock Price & Analysis
CTEC1N Stock Chart & Stats
- Day’s Range
- MXN 58.67 - MXN 58.67
- 52-Week Range
- MXN 58.67 - MXN 59.76
- Previous Close
- MXN 58.67
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 116.32B
- Enterprise Value
- MXN 5.45B
- Total Cash (Recent Filing)
- MXN 99.51M
- Total Debt (Recent Filing)
- MXN 1.75B
- Price to Earnings (P/E)
- 51.9
- Beta
- 0.07
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 2.14
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.52%
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Model
ConvaTec’s consumable products generate repeat demand because ostomy, wound care, continence and infusion users require ongoing replenishment. This recurring model supports revenue visibility, strengthens customer retention and provides a durable foundation for growth across healthcare settings.
Improving Operating Margins
Revenue growth alongside substantial operating-margin expansion indicates that productivity and cost control are improving the earnings profile. Although net income remains modest, stronger operating profitability can support reinvestment, resilience and better earnings quality over coming quarters.
Infusion And Product Growth
Strong Infusion Care demand, particularly outside diabetes, gives ConvaTec a growth engine supported by recurring therapy consumables. Continued product launches and capacity investment could broaden the portfolio, increase adoption and sustain organic growth beyond the current reporting period.
Bears Say
Higher Leverage
The increase in debt relative to equity reduces financial flexibility and makes results more sensitive to earnings pressure or financing costs. Higher leverage can constrain capital allocation and leave less room to absorb operational setbacks while the company funds growth investments.
InnovaMatrix Collapse
The sharp InnovaMatrix sales decline and impairment demonstrate that part of the portfolio has materially underperformed expectations. Although management expects the product to become small, the lost revenue and margin contribution weaken near-term results and highlight execution risk in newer offerings.
Multi-Year FDA Remediation
A remediation program extending through 2027 creates a persistent operational burden and requires sustained management attention. Even without current product-safety or manufacturing disruption, prolonged quality-system work can increase execution complexity and delay the full realization of strategic priorities.
ConvaTec News
CTEC1N FAQ
What was ConvaTec’s price range in the past 12 months?
What is ConvaTec’s market cap?
When is ConvaTec’s upcoming earnings report date?
How were ConvaTec’s earnings last quarter?
Is ConvaTec overvalued?
Does ConvaTec pay dividends?
What is ConvaTec’s EPS estimate?
How many shares outstanding does ConvaTec have?
What happened to ConvaTec’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ConvaTec?
What is the TipRanks Smart Score and how is it calculated?
ConvaTec Stock Smart Score
Company Description
ConvaTec
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Jonathan Peter Mason
- Employees
- 10,910
- Website
- www.convatecgroup.com
- Address
- 20 Eastbourne Terrace, London, GL, W2 6LG, GB
ConvaTec (CTEC1N) Earnings & Revenues
CTEC1N Earnings Call
Earnings Call SentimentPositive
The call conveyed an upbeat, constructive tone: management confirmed they are on track for FY '26 targets (revenue growth, at least 23% operating margin, and continued double‑digit EPS growth), announced a USD 200m buyback and highlighted robust Infusion Care momentum, multiple product launches with strong clinical evidence (notably ConvaNiox) and clear CapEx to support long-term growth. Key challenges include the disappointing InnovaMatrix performance and impairment, softer wound care trading in parts of H1, H1 cash timing pressures, currency headwinds and a multi-year FDA remediation program. On balance, the positive execution on strategy, operational productivity, financing actions and high-confidence Infusion Care order visibility outweigh the near-term setbacks.
View all MX:CTEC1N earnings summariesCTEC1N Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 1 | 13 |
| Technical Analysis | 2 | 1 | 2 |
| Moving Averages | 1 | 0 | 11 |
